Drugs / CS5001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05279300 | Mar 2022 → Jun 2027 expected | adult lymphoma | CStone Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS5001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05279300 ↗ |
| Target | ROR1 | “CS5001, an Anti-ROR1 Antibody-Drug Conjugate” NCT05279300 ↗ |